MLTX vs MPLT

MoonLake Immunotherapeutics vs MapLight Therapeutics, Inc. — Valuation Comparison 2026

MLTX

Biotechnology
MoonLake Immunotherapeutics
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$18.68
Last close
Models
7/13
Active
VS

MPLT

Biotechnology
MapLight Therapeutics, Inc.
Quality
5.0
out of 10
Value Trap
Price
$29.78
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MLTX Fair ValueMLTX Upside MPLT Fair ValueMPLT Upside
Bayesian DCF Intrinsic $6.65 -64.4% $8.54 -71.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.45 -97.3% $2.30 -92.3%
Dynamic NAV Asset-Based $4.61 -75.3% $7.03 -76.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MLTX vs MPLT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MLTX vs MPLT — Which Stock Is More Undervalued?

MPLT scores higher with a 5.0/10 quality rating vs MLTX's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MoonLake Immunotherapeutics (MLTX) and MapLight Therapeutics, Inc. (MPLT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MLTX currently trades at $18.68 with a QOC of 4.0/10, while MPLT trades at $29.78 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).